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NTherapeutic drug monitoring (TDM), which involves mea-
surement of drug or active metabolite levels and anti-drug
antibodies, is a promising strategy that can be used to
optimize inflammatory bowel disease therapeutics. It is
based on the premise that there is a relationship between
drug exposure and outcomes, and that considerable inter-
individual variability exists in how patients metabolize the
drug (pharmacokinetics) and the magnitude and duration
of response to therapy (pharmacodynamics). Therefore,
the American Gastroenterological Association has priori-
tized clinical guidelines on the role of TDM in the man-
agement of inflammatory bowel disease. To inform these
clinical guidelines, this technical review was developed in
accordance with the GRADE (Grading of Recommendations
Assessment, Development, and Evaluation) framework for
interventional and prognostic studies, and focused on the
application of TDM for biologic therapy, specifically anti-
tumor necrosis factorLa agents, and for thiopurines.
Focused questions address the benefits and risks of a
strategy of reactive TDM (in patients with active inflam-
matory bowel disease) to guide treatment changes
compared with empiric treatment changes, and the bene-
fits and risks of a strategy of routine proactive TDM
(during routine clinical care in patients with quiescent
disease) compared with no routine TDM. Additionally, the
review addresses the benefits and risks of routine mea-
surement of thiopurine methyltransferase enzyme activity
or genotype before starting thiopurine therapy compared
with empiric weight-based dosing and explores the per-
formance of different trough drug concentrations for
antiLtumor necrosis factor agents and thiopurines to
inform clinical decision making when applying TDM in a
reactive setting. Due to a paucity of data, this review does
not address the role of TDM for more recently approved
biologic agents, such as vedolizumab or ustekinumab.
uring the last decade, the approach to treating in-Most current article
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http://dx.doi.org/10.1053/j.gastro.2017.07.031Dflammatory bowel diseases (IBD) has evolved from
controlling symptoms and achieving clinical remission to
decreasing progressive bowel damage and disability through
the timely and optimal use of biologic therapies and/orimmunomodulator agents. One emerging strategy in opti-
mizing the use of biologics is therapeutic drug monitoring
(TDM), which involves measuring serum drug concentration
(typically at trough) and anti-drug antibodies (ADAbs).1 The
proposed rationale for TDM is that a systematic and algo-
rithmic assessment of drug concentration (and ADAb) can
help objectively evaluate potential reasons for failure of
therapy and define next steps in management, and proac-
tively provide opportunities for optimizing therapy to maxi-
mize chances of treatment success. This is based on clinical
observations, including the presence of an exposur-
eresponse relationship in which serum drug concentration
determines the magnitude of the clinical response; inter-
individual variability in drug clearance through both
immune-mediated (formation of neutralizing ADAb) and
nonimmune-mediated mechanisms (associated with high
inflammatory burden), which contribute to differences in
drug concentration; and concept of mechanistic failure, in
which, despite adequate drug exposure at site of receptor,
some patients may not respond to a particular class of bi-
ologics due to differences in underlying disease patho-
physiology.2–4 A similar concept of TDM also applies to
thiopurines, wherein thiopurine methyltransferase (TPMT)
enzyme activity (or genotype) influences drug metabolism
and concentration of drug metabolites, 6-thioguanine
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SECTION(6-TGN) and 6-methylmercaptopurine (6-MMP), which have
been variably associated with drug efficacy and safety.5,6
However, despite increasing adoption of TDM in clinical
practice, there is limited synthesis of evidence and a lack of
guidance on the benefits, risks, and overall approach to TDM
in the management of IBD. Therefore, the American
Gastroenterological Association (AGA) has prioritized this
topic for the generation of clinical guidelines.
Objectives of the Review
This technical review addresses the following focused
clinical questions on different strategies of TDM with
biologics and thiopurines to improve patient outcomes:
1. In biologic-treated patients with active IBD, what are
the benefits and risks of reactive TDM (in response to
active disease) to guide treatment decisions over a
strategy of empiric treatment changes? If TDM is
adopted, what is the association between different
target drug concentrations and clinical outcomes?
2. In biologic-treated patients with quiescent IBD, what
are the benefits and risks of routine proactive TDM-
guided dose adaptation?
3. What are the benefits and risks of routinemeasurement
of TPMT enzyme activity or genotype, before starting
thiopurines, over empiric weight-based dosing?
4. In thiopurine-treated patients with active IBD or
suspected to have thiopurine-related toxicity, what
are the benefits and risks of reactive TDM with
measurement of 6-TGN and 6-MMP levels, to guide
treatment decisions over a strategy of empiric treat-
ment changes? If TDM is adopted, what target 6-TGN
cutoff is optimal for improving clinical outcomes?
5. In thiopurine-treated patients with IBD on standard
weight-based therapy, what are the benefits and risks
of routine proactive TDM-guided dose adaptation?
The results of this technical review were used to inform
the development of the accompanying clinical guidelines on
TDM in IBD. Of note, we focused on anti-tumor necrosis factor
(TNF)-a agents only when reviewing TDM for biologics, and
no distinction was made between monotherapy and combi-
nation therapy in this setting. While the same concepts may
apply to other biologics (eg, vedolizumab and ustekinumab),
their mechanism of action is distinct from anti-TNF agents
and, at this point, there are very limited published data on the
role of TDM for these agents to inform guidelines. Therefore,
nonanti-TNF biologics are not discussed in these guidelines.
Similarly, due to limited use, the technical review team and
the guideline panel, with the approval of the AGA Governing
Board, opted not to synthesize evidence on the role of TDM
for methotrexate, cyclosporine, and tacrolimus.
Methods
Overview
This technical review and the accompanying guideline were
developed using the GRADE (Grading of RecommendationsAssessment, Development, and Evaluation) framework.7 The
members of the technical review panel were selected by the
AGA Clinical Guidelines Committee based on their clinical
content and guidelines methodological expertise and went
through a thorough vetting process for potential conflicts of
interest. Through an iterative process, and in conjunction with
the guideline panel, the participants developed focused clinical
questions on the role of TDM for anti-TNF agents and thio-
purines deemed relevant for clinical practice that the guideline
would address. After the focused questions were approved by
the AGA Governing Board (in December 2015), the technical
review team formulated the clinical questions, identified rele-
vant patient-important outcomes, systematically reviewed and
summarized the evidence for each outcome across studies, and
then rated the quality of the evidence across all outcomes for
each clinical question.Formulation of Clinical Questions
Using the PICO format, which frames a clinical question by
defining a specific population (P), intervention (I), comparator
(C), and outcomes (O), the team finalized 5 questions (Table 1).
The first set of PICOs focused on TDM for anti-TNF agents, and
the second set of PICOs on TDM for thiopurines. Questions
focused on comparing different strategies of TDM classified as
reactive TDM or routine proactive TDM. Reactive TDM is
defined as TDM performed in response to active IBD (ongoing
active inflammation based on biochemical, endoscopic, or
radiologic assessment, usually with symptoms) after a period of
quiescent disease, or continued inflammation without achieving
remission with index therapy; of note, a small fraction of pa-
tients, especially those with active Crohn’s disease (CD) (active
inflammation) may be asymptomatic, and the concept of reac-
tive TDM also applies to those patients. Routine proactive TDM
was defined as TDM performed in patients regardless of clinical
status (generally in quiescent disease) periodically as part of
routine clinical care. The comparator strategy relied on empiric
treatment changes—for anti-TNF agents, this focused on a
stepwise approach of empiric escalation of therapy or switching
to different treatment agents within or outside the index class
(ie, with same putative mechanism of action or with a different
mechanism of action). Potentially relevant patient-important
outcomes were considered and rated in terms of importance
through consensus; clinical remission was considered critical
for decision making, whereas mucosal healing (endoscopic
remission), serious adverse events, cost, drug or metabolite
concentration, and patient convenience were considered
important outcomes. The panel recognized limitations of using
a clinical disease activity as an outcome measure, especially for
CD, but still believed that in the current context, it is the most
consistently reported outcome in clinical practice and is
important for patients.Search Strategy and Study Selection Criteria
The literature search was performed on March 6, 2016, and
details of the search strategy are reported in the
Supplementary Material. Studies were selected for inclusion
based on PICO theme. Due to lack of high-quality randomized
controlled trials (RCTs) informing each question, the study
selection and data synthesis approach were customized for
each question. For PICO #1 (reactive TDM) and PICO #2
Table 1.Focused Clinical Questions and Corresponding Questions in PICO (Population, Intervention, Comparator, and Outcomes) Format Addressed in This
Technical Reviewa
Focused question
PICO question
Population Intervention Comparator Outcomes
Biologic therapy in IBD
1. In adults with active IBD treated with
anti-TNF agents, is reactive TDM to guide
treatment changes superior to no TDM
and empirically escalating dose or
switching therapies?
Adults with active IBD, being
treated with anti-TNF
agents
Reactive TDM (measurement of
trough and anti-drug
antibodies), in response to
new or continuing active IBD),
to guide treatment changes
No reactive TDM, with either
empiric dose escalation, or
switching therapy
Clinical remission or response
2. In adults with quiescent IBD treated with
anti-TNF agents, is routine proactive
TDM to guide prospective treatment
changes superior to no TDM?
Adults with quiescent IBD,
being treated with anti-TNF
agents
Routine proactive TDM
(measurement of trough drug
level and anti-drug antibodies),
to guide ongoing treatment,
regardless of clinical status
No routine TDM, in absence of
change in clinical status
Clinical remission or response
Thiopurine therapy in IBD
3. In patients with IBD being started on
thiopurines, is routine TPMT enzyme
activity or genotype measurement (to
guide dosing) superior to no TPMT
measurement (with empiric weight-based
dosing of thiopurines)?
Adults with IBD, starting
thiopurine therapy
Routine TPMT measurement
(enzyme activity or genotype)
to guide thiopurine dosing
No TPMT measurement, with
empiric weight-based
thiopurine dosing
Serious adverse events
4. In patients with active IBD treated with
thiopurines or with side effects thought to
be due to thiopurine toxicity, is reactive
TDM to guide treatment changes supe-
rior to no TDM with empiric treatment
changes?
Adults with active IBD, being
treated with thiopurines,
or with side effects
concerning for thiopurine
toxicity
Reactive TDM (measurement of 6-
TGN and 6-MMP), in response
to active IBD or side effects
concerning for thiopurine
toxicity, to guide treatment
changes
No reactive TDM, with empiric
treatment changes
Clinical remission or response
Serious adverse events
5. In patients with IBD treated with thio-
purines, is routine TDM to guide thio-
purine dosing superior to empiric
weight-based dosing?
Adults with IBD, being treated
with thiopurines
Routine proactive TDM
(measurement of 6-TGN and
6-MMP), to guide ongoing
treatment, regardless of
clinical status
No routine TDM, with empiric
weight-based thiopurine
dosing
Clinical remission or response
Serious adverse events
aBesides these questions, the technical review also addresses the performance of different trough levels for infliximab, adalimumab, certolizumab pegol, and golimumab in
clinical practice to inform PICOs #1 and #2.
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RCTs, comparative observational studies, or cohort studies in
adults with IBD, with either active IBD or quiescent disease,
treated with anti-TNF agents, who underwent TDM (ie, mea-
surement of drug levels and/or ADAbs). Due to the paucity of
high-quality RCTs and observational comparative studies for
PICOs #1 and #2, we relied on cohort studies that reported
differences in outcomes of patients depending on trough level
and/or presence of ADAb, in response to empiric dose escala-
tion and/or switching therapies. This provided indirect evi-
dence on potential risks and benefits of TDM-guided treatment
decisions compared with empiric treatment changes. For PICO
#3 on the role of TPMT enzyme activity or genotype before
starting thiopurines, we included RCTs in patients with IBD
who were started on thiopurines, based on either TPMT guid-
ance or empirically, and evaluated safety and efficacy of ther-
apy. For PICOs #4 and #5 on application of TDM strategies for
thiopurines, a similar approach was adopted, wherein, if high-
quality RCTs or observational comparative studies were lack-
ing, cohort studies were used to inform evidence indirectly.
To inform optimal target trough concentrations and their
performance, we initially searched for RCTs or observational
comparative studies that report differences in patient outcomes
based on different target trough concentration thresholds. In
the absence of comparative studies, we chose cohort and cross-
sectional studies that reported correlation between different
thresholds and presence or absence of clinical remission (or
response) and assessed the pooled proportion of patients “not
in remission” above certain predefined thresholds. Of note,
these were not framed as PICOs, but are rather presented semi-
quantitatively to inform clinical guidelines.Statistical Analysis
When comparative studies were available, pooled relative
risk (RR) and 95% confidence intervals (CI) were calculated
using DerSimonian-Liard random-effects model.8 For PICOs #1
and #4, as well as in assessing performance of different trough
concentration thresholds, we estimated weighted pooled pro-
portion of patients in different relevant categories, using
random-effects meta-analysis. Statistical heterogeneity was
assessed using the I2 statistic, and values>50%were considered
suggestive of significant heterogeneity.9 Small study effects were
examined using funnel plot symmetry and Egger’s regression
test, though it is important to recognize that these tests are un-
reliablewhen the number of studies is<10.10 Statistical analyses
were performed using RevMan, version 5.3 (Cochrane Collabo-
ration, Copenhagen, Denmark) or Comprehensive Meta-Analysis
software, version 2 (Biostat, Englewood, NJ).Quality of Evidence
The GRADE approachwas used to rate the quality of evidence
(or confidence in summary effect estimates).7 In this approach,
direct evidence from RCTs starts at high quality and can be rated
down based on risk of bias in the body of evidence (or study
quality), indirectness (addressing a different but related popu-
lation, intervention, or outcome, from the one of interest),
imprecision (of summary estimate and boundaries of 95% CI),
inconsistency (or heterogeneity), and/or publication bias to
levels of moderate, low, and very low quality. Due to inherent
limitations in observational studies (ie, selection bias,unmeasured confounding), evidence derived from observational
studies starts at low quality, and is then potentially downgraded
based on the factors mentioned, or can be upgraded in case of
doseresponse relationship and large magnitude of effect.Evidence-to-Decision Framework
Because this technical review was used to inform the
development of clinical guidelines, besides a comprehensive
riskbenefit analysis and the accompanying quality of evi-
dence, information about additional factors, such as patients’
values and preferences, cost-effectiveness, and resource utili-
zation were also considered.Primer on Therapeutic Drug
Monitoring With AntiLTumor
Necrosis Factor Agents
Biologics, more specifically monoclonal antibodies, are
protein-based drugs that can bind to an antigen with great
specificity and possess powerful effector functions. After
parenteral administration (subcutaneous or intravenous),
monoclonal antibodies are distributed mainly in the central
compartment and are eliminated through proteolytic
catabolism after receptor-mediated endocytosis in the cells
of the reticuloendothelial system.11 Unique for biologics is
that the immune system can recognize these molecules as
non-self, leading to a humoral or cell-mediated immune
response with the formation of ADAb.12 ADAb impair the
efficacy of the drug by either blocking the antigen-binding
site or by forming complexes with the molecule, leading to
up-regulated clearance. Because of the formation of ADAb
and changes in other covariates, such as body mass, albu-
min, C-reactive protein (CRP), and others, considerable
inter-individual variability in drug exposure is observed.13
The drug concentration at the site of the receptor de-
termines the magnitude of the pharmacologic response and
monitoring drug exposure in individual patients might be
helpful to guide therapeutic decisions in clinical practice.
Various measures can be used for drug exposure, but serum
trough concentrations, or the concentration of drug just
before the next administration, is used most commonly.
Assessing the exposureresponse relationship in individual
patients can be done by TDM, with measurement of trough
concentrations at various time points. Because of different
dosing regimens during induction vs maintenance therapy,
ideal thresholds where the exposureresponse relationship
is optimal are different in different phases of therapy. For
example, patients may show impaired response to therapy
due to pharmacokinetic failure because of inadequate drug
exposure as a result of increased drug clearance. This is
distinct from the scenario where patients have adequate
drug exposure but show no response to therapy due to
mechanistic failure because the disease is not mediated by
the antigen that is targeted by the molecule.14 In the former
scenario, dose escalation may result in recaptured response,
and in the latter scenario, switching to a drug out of class
with another mechanism of action might be the preferred
pharmacologic strategy.
September 2017 AGA Review of Therapeutic Drug Monitoring in IBD 839
AG
A
SE
CT
IO
NAssays for Therapeutic Drug Monitoring of
AntiTumor Necrosis Factor Agents
Different assay formats exist to measure drug and ADAb,
of which the most commonly used are the enzyme-linked
immunosorbent assay (ELISA), homogenous mobility shift
assay (HMSA), and electrochemiluminescence immunoassay
(ECLIA).15 The main characteristics of the assays used for
anti-TNF currently available in the United States are out-
lined in Supplementary Table 1. ADAb assays that are car-
ried out in a fluid phase environment (HMSA, ECLIA, and
radioimmunoassay [RIA]) are more sensitive to detect low-
affinity antibodies than solid-phase ADAb assays (ELISA).
For measuring ADAbs, no international analytical standard
is currently available and different assays report different
ADAb titers (eg, mg/m, mg/mL equivalents, U/mL, and AU
[arbitrary units]/mL).
In general,measurement of infliximab concentrationswith
various assays was found to be relatively comparable with
acceptable specificity, accuracy, and reproducibility between
assays. This was shown in a recent large comparative study
evaluating various assays for the measurement of inflix-
imab.15 Agreement between assaymethods was quantified by
the intra-class correlation coefficient of the Janssen infliximab
assay (ELISA) with the assay from KU Leuven (ELISA), San-
quin (ELISA), Dynacare (ELISA), and Esoterix/LabCorp
(ECLIA) and was 0.960, 0.895, 0.931, and 0.971, respectively.
Infliximab recovery of a sample of pooled healthy control
serum spiked with 5 mg/mL infliximab ranged between 7%
and þ20% of the nominal concentration, which was deter-
mined by the authors to bewithin the acceptable range.16,17 In
the same comparative study, ADAbs to infliximab were
detected specifically and reproducibly.15 ADAbs to infliximab
methods of Janssen (ECLIA), Sanquin (RIA), and Esoterix/
LabCorp (ECLIA) were more resistant to infliximab interfer-
ence than Dynacare (ELISA) and KU Leuven (ELISA), which
were affected by infliximab concentrations of 2 mg/mL.
Although the correlation between ADAb assays might be
reasonable, comparing the quantitative result between assays
is less ideal, that is, although quantitative ADAbs detected
using HMSA, ELISA, or ECLIA will be very different, their re-
sults should be interpreted in the appropriate clinical context
and drug concentration levels (the latter would be quantita-
tively comparable across different assays). A comparison of 3
assays for the detection of ADAb to infliximab (bridging ELISA,
RIA, and HMSA) showed that overall, assays provided similar
guidance for clinical practice in most patients with loss of
response.18
For golimumab, 2 comparative studies evaluated 2
commercially available tests (Promonitor [ELISA] and San-
quin [ELISA]) for the detection of drug in serum, which
showed excellent correlation and agreement.19 For adali-
mumab, 1 comparative study evaluated a commercially
available ELISA (Matriks Biotek, Ankara, Turkey) and HMSA
(Prometheus Laboratories, Inc, San Diego, CA) for the detec-
tion of drug in serum in 23 patients treatedwithmaintenance
adalimumab during a 96-week follow-up period.20 HMSA
measured consistently lower concentrations than ELISA,
resulting in a 2-fold difference in adalimumab trough cutoffsthat correlated with clinical remission. These data warrant
caution when extrapolating cutoffs across assays, especially
for adalimumab. Currently, data on the comparison of assays
for certolizumab pegol are lacking.
Interpreting Results of Therapeutic Drug
Monitoring
All available drug assays report both drug concentration
and ADAbs. In interpreting these, we suggest evaluating drug
concentration first. In the presence of therapeutic drug con-
centration, ADAbs are generally undetectable. If detected,
ADAbs are generally low concentration and, consequently, can
have a limited effect on drug pharmacokinetics. In a combined
retrospective analysis of 4 studies, it was observed that both
infliximab concentration (odds ratio, 1.8; 95% CI, 1.32.5)
and ADAbs to infliximab (odds ratio, 0.57; 95%CI, 0.390.81)
were independently associated with biochemical remission
(CRP5mg/L) in patientswith CDonmaintenance infliximab
therapy.21 Detecting both infliximab and ADAbs to infliximab
in the same sample was observed in a minority of samples
(7.3%), suggesting that impaired efficacy is likely a result of
both a mechanism of accelerated drug pharmacokinetics and
direct blocking of drug activity by ADAbs.
In patients who are failing despite a therapeutic drug
concentration, regardless of ADAb, this can be caused by
mechanistic failure, and patients might benefit from switch-
ing to a drug out of class. On the other hand, if drug concen-
tration is subtherapeutic or undetectable, then we suggest
evaluating ADAbs. If ADAbs are detectable, particularly at
high titers, then it suggests that drug clearance is increased
due to immune-mediated mechanisms and switching to a
drug in class with the same mechanism of action but other
molecular structure may be the preferred pharmacologic
option. If ADAb are not detectable, then clearance is up-
regulated due to nonimmune-mediated mechanisms, such
as high inflammatory burden resulting in rapid drug utiliza-
tion and/or excessive drug wasting due to fecal loss (indi-
cated by elevated CRP and/or fecal calprotectin and/or low
albumin).13,22 Table 2 summarizes the conventionally pro-
posed interventions based on TDM in the reactive setting in
patients with secondary loss of response, and the estimated
distribution of patients in each category, based on 3 obser-
vational studies.23–25 Most importantly, these possible in-
terventions at time of secondary loss of response remain to be
confirmed in a well-designed prospective study.
Results
Question 1: In Adults With Active Inflammatory
Bowel Disease Treated With AntiTumor
Necrosis Factor Agents, Is Reactive Therapeutic
Drug Monitoring to Guide Treatment Changes
Superior to No Therapeutic Drug Monitoring
and Empirically Escalating Dose or
Switching Therapies?
Key message. In patients with active IBD treated with
anti-TNF agents, there may be a benefit of reactive TDM to
Table 2.Proposed But Not Yet Prospectively Validated Interventions Based on Therapeutic Drug Monitoring in the Reactive
Setting in Patients With Secondary Loss of Response, and Observed Distribution of Patients in Different Categories
Based on Observational Studies23–25,88
Anti-drug antibody
(ADAb)
Drug concentration
Subtherapeutic drug trough concentration Therapeutic drug trough concentration
Undetectable ADAbs Nonimmune-mediated pharmacokinetic failure, 51%
Y
Dose escalate by either increasing the dose or
decreasing the interval between drug
administrations
Mechanistic failure, 25%
Y
Switch to drug out of class
Detectable ADAbs Immune-mediated pharmacokinetic failure, 19%
Y
Consider optimizing index therapy in case of low-level
ADAbs, or switch to drug in class and consider
adding an immunomodulator in patients with high
level ADAbs
Mechanistic failure, 5%
Y
Switch to drug out of class and consider adding an
immunomodulator in case of switching to a biologic
840 Vande Casteele et al Gastroenterology Vol. 153, No. 3
AGA
SECTIONguide treatment changes over empirically escalating dose or
switching therapies (very-low-quality evidence).
Effect estimates. One small RCT26 and 3 observational
studies23–25 in patients with IBD on maintenance therapy
with anti-TNF agents were used to inform this question. An
additional RCT designed to address this question was also
identified on ClinicalTrials.gov (Number: NCT01960426).
However, that trial was terminated very shortly after start
due to difficulties with recruitment.
In a Danish RCT, 69 patients with CD on maintenance
therapy with infliximab who developed CD-related symp-
toms were randomized to either TDM-guided treatment
changes (based on trough concentration and presence of
antibodies to infliximab; n ¼ 33) vs empiric dose escalation
(5 mg/kg every 4 weeks; n ¼ 36).26 In this trial, infliximab
and ADAbs to infliximab were measured by fluid-phase
RIA.27 Infliximab trough concentration was classified as
therapeutic (0.5 mg/mL) or subtherapeutic (<0.5 mg/mL),
and ADAb to infliximab as detectable or undetectable (limit
of quantification, 10 U/mL). On intention-to-treat analysis
12 weeks after intervention, 10 of 33 patients (30.3%) in
the TDM-guided treatment group vs 14 of 36 (38.9%) in the
empiric dose-escalation arm achieved clinical remission (RR
of achieving clinical remission, 0.78; 95% CI, 0.401.51).
Based on the investigator’s criteria, the majority of pa-
tients in the TDM-guided dosing arm (76%) had a thera-
peutic infliximab trough (0.5 mg/mL) at the time of
secondary loss of response, suggesting mechanistic failure,
and these patients were treated with discontinuation of
infliximab and switching out of biologic class (nonanti-
TNF-mediated therapy), or to corticosteroids and/or
immunomodulators, or by targeting potential noninflam-
matory causes of symptoms. Treatment failure was pre-
sumably due to immunogenicity of infliximab in 20% of
patients (infliximab trough concentrations <0.5 mg/mL with
detectable ADAbs to infliximab), who were treated with
switching within class (to an alternate anti-TNF agent), and
only 4% of patients had nonimmune-mediatedpharmacokinetic failure (with infliximab trough concentra-
tions <0.5 mg/mL and undetectable ADAbs to infliximab),
who were managed with infliximab dose escalation to 5 mg/
kg every 4 weeks. In contrast, all patients randomized to
nonTDM-guided dosing underwent empiric dose escala-
tion at time of secondary loss of response.
Three observational studies also contributed to the evi-
dence on the role of reactive TDM after secondary loss of
response in patients on maintenance anti-TNF therapy.23–25
These studies are summarized in Supplementary Table 2. In
these studies, all patients with secondary loss of response
underwent empiric dose escalation as standard of care.
Subsequently, difference in response to dose escalation was
retrospectively assessed in patients in different strata based
on anti-TNF trough concentration and presence or absence
of ADAbs, that is, what proportion of patients with thera-
peutic trough without ADAb (mechanistic failure), subther-
apeutic trough without ADAbs (nonimmune-mediated
pharmacokinetic failure), and subtherapeutic trough with
ADAbs (immune-mediated pharmacokinetic failure),
responded to empiric escalation of therapy. On pooled
analysis of 2 studies, overall 60 of 134 (45%) patients
responded to dose escalation.23,25 On evaluating by different
strata, 41 of 50 (82%) patients with nonimmune-mediated
pharmacokinetic failure responded to dose escalation (RR of
achieving response with dose escalation vs empiric dose
escalation, 1.71; 95% CI, 1.392.11). In contrast, only 2 of
24 (8%) patients with immune-mediated pharmacokinetic
failure (with high ADAbs) responded to dose escalation (RR
vs empiric dose escalation, 0.26; 95% CI, 0.080.86). Yanai
and colleagues24 observed similar results—55% of loss of
response events due to nonimmune-mediated pharmaco-
kinetic failure (no/low ADAbs) vs 15% events due to
immune-mediated pharmacokinetic failure (high ADAbs)
responded to dose escalation with index agent.
In contrast to the RCT by Steenholdt et al,26 only 139 of
464 (30%) patients/loss of response events in observa-
tional studies were classified as being due to mechanistic
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concentration thresholds (infliximab trough, 2.03.8 mg/
mL; adalimumab trough, 4.54.9 mg/mL) (Table 2).26 The
majority (235 of 464 [51%]) of patients in these studies
were deemed to have secondary loss of response due to
nonimmune-mediated pharmacokinetic failure (subthera-
peutic trough without ADAbs) (vs 4% in RCT), and 19% (90
of 464) of patients were classified as having immune-
mediated pharmacokinetic failure (subtherapeutic trough
with high ADAbs) (vs 20% in RCT).
Besides dose escalation, an alternative empiric response
to secondary loss of response may be switching to an
alternative agent (either within class with same mechanism
of action, or outside of class with a different mechanism of
action). Roblin et al25 observed that 16 of 52 (31%) patients
responded to empiric switching to a different anti-TNF after
failure of empiric dose escalation. On retrospectively
applying TDM, only 2 of 29 (7%) patients with therapeutic
trough with index anti-TNF responded to switching to a
different anti-TNF agent. Among patients with low trough,
12 of 15 (80%) patients with immune-mediated pharma-
cokinetic failure (high ADAbs) responded to switching to
another anti-TNF agent, whereas only 2 of 8 (25%) patients
with nonimmune-mediated pharmacokinetic failure
responded to switching to a different anti-TNF agent after
failure to respond to empiric dose escalation.
Yanai et al24 made similar observations—among pa-
tients with high ADAbs at time of loss of response, the
likelihood of response to switching to different anti-TNF
was much higher compared with dose escalation of index
agent (6 months after intervention, 50% vs 15%; P ¼ .03).
Among patients with low ADAbs at time of loss of response,
likelihood of response to dose escalation was higher
compared with switching to different anti-TNF (6 months
after intervention, 50% vs 40%; P ¼ .02).24 Following the
TDM framework, they observed that among patients with
therapeutic trough at time of secondary loss of response
(mechanistic failure), likelihood of response to switching
out of biologic class (to a nonanti-TNF-mediated mecha-
nism) was numerically higher compared with attempts at
anti-TNF optimization (based on ADAb level, either dose
escalation or switching within class) (6 months after inter-
vention, 78% vs 44%; P ¼ .09).
Quality of evidence. The single RCT that informed
this question was at high risk of bias, with a high degree of
nonadherence to protocol (only 19 of 33 patients random-
ized to TDM-guided intervention were handled accordingly,
and 17 completed the trial per protocol). The threshold of
therapeutic infliximab trough used in this trial (0.5
mg/mL) is probably too low (and a significant proportion of
patients may have been incorrectly labeled as having
mechanistic failure); the distribution of patients in terms of
TDM-defined reasons for treatment failure (and subsequent
intervention) was very different from what is observed in
real-world observational studies, resulting in indirectness.
Additionally, the summary estimate was very imprecise,
with very wide CIs.
In contrast to RCT-level evidence, observational studies
suggest a significant difference in likelihood of response toempiric dose escalation (or switching to different therapy),
depending on which TDM-defined stratum a patient falls
into. Due to the observational nature of these studies with
inherent risks of bias, and low event rates in included
studies (resulting in imprecision), the quality of evidence
derived from observational studies was rated as very low.
Therefore, the overall body of evidence supporting the use
of reactive TDM to guide treatment changes over empiric
dose escalation or switching therapies in patients with IBD
treated with anti-TNFs with secondary loss of response is
very low.
Potential harms of intervention. TDM is performed
through a blood test generally just before next due dose,
which can cause a small inconvenience. However, there are
additional potential harms of downstream interventions
from TDM testing because thresholds for therapeutic trough
concentration and ADAbs are not very well-defined. Ther-
apeutic trough is dynamic, depending on phase of inter-
vention (induction vs maintenance therapy), treatment
target (clinical remission vs endoscopic remission), and
phase of disease activity (severe active vs mild active dis-
ease; luminal disease vs perianal disease).28–31 Likewise,
threshold ADAb levels that define immunogenicity and
predict low likelihood of response to dose escalation are not
well-defined and are variable across assays. Therefore, due
to variable thresholds, which have suboptimal discrimina-
tory performance, strict adherence to TDM-guided treat-
ment changes can potentially result in inappropriate
treatment changes in some patients who might have
responded to empiric escalation of therapy.
In contrast, empiric escalation of therapy can impose
significant additional costs of escalated therapy, result in
potentially futile therapy, and delay more effective therapy,
particularly if repeated cycles of empiric dose escalation are
attempted. In addition, in patients with immune-mediated
pharmacokinetic failure (with established ADAbs), addi-
tional drug exposure is likely to result in immediate and
delayed hypersensitivity reactions, which are generally mild
but can be severe. Similarly, excessive drug exposure can
conceivably result in higher risk of drug-related adverse
events, such as serious infections, although this has not been
consistently observed.
Discussion. Approximately one third of IBD patients
fail to respond to anti-TNF therapy and, of those who do
respond initially, secondary loss of response is an important
clinical problem and occurs in up to 40% of patients during
the first year of therapy.32,33 Once noninflammatory com-
plications, such as strictures and overlapping irritable bowel
syndrome, are excluded, potential causes of this phenome-
non include low drug exposure because of immune- or
nonimmune-mediated clearance mechanisms, or mecha-
nistic failure whereby nonTNF-mediated cytokine path-
ways may be activated. Given the complexity of this
problem, it is hypothesized that TDM may be helpful to
guide appropriate treatment changes. However, based on
current evidence, the magnitude of benefit of this approach
over empiric dose escalation is uncertain. Several factors
contribute to this uncertainty. First, the included studies
were at high risk of bias, with poor adherence to protocol,
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olds for optimal trough and ADAbs. Second, most studies
relied on clinical disease activity with or without biochem-
ical or endoscopic confirmation of disease activity, to initiate
intervention, and to measure success of intervention. Clin-
ical disease activity has modest correlation with endoscopic
disease activity, risk of surgery, and disease-related com-
plications, at least in patients with CD.34 Third, besides the
mild inconvenience of blood test for TDM, there is potential
misclassification and missed treatment optimization op-
portunities due to suboptimally defined thresholds for both
drug concentration and ADAb. In contrast, empiric dose
escalation may result in additional costs, higher likelihood of
futile treatment and disease-related complications, and
potentially delay more effective therapy.
Overall, the riskbenefit profile may favor reactive
TDM-guided treatment changes over empiric dose escala-
tion. In the Danish RCT, in patients with secondary loss of
response to infliximab, accumulated costs related to treat-
ment of CD during a 12-week period were significantly
lower (34%) for those who underwent TDM-guided therapy
vs empiric dose escalation of infliximab (V6038 vs V9178,
respectively; P < .001).26 In a decision analysis, Velayos
et al35 reported TDM-guided treatment strategy dominated
empiric dose escalation (numerically lower costs, and
higher quality-adjusted life year), which was stable across
multiple sensitivity analyses with variable model inputs.
They estimated that increasing the cost of the test >25-fold
their base-case scenario ($5700) resulted in the testing
strategy no longer being less expensive than the empiric
strategy ($37,267 vs $37,266).
It is important to note that all studies used to synthesize
this evidence included only those patients with secondary
loss of response on maintenance infliximab or adalimumab,
that is, patients who had responded initially to therapy and
subsequently lost response during the maintenance phase of
therapy. It is difficult to extrapolate results of a reactive
TDM-based treatment strategy vs empiric treatment esca-
lation to induction therapy. Recent studies in patients
treated with infliximab and adalimumab suggest that sub-
optimal drug exposure can play a role during the induction
phase, particularly in patients with a high inflammatory
burden and/or individual characteristics that are associated
with increased clearance, such as low albumin concentra-
tion.36,37 Knowing what thresholds are associated with
outcomes shortly after starting therapy could be useful in
guiding treatment decisions.
Question 2. In Adults With Quiescent
Inflammatory Bowel Disease Treated With
AntiTumor Necrosis Factor Agents, Is Routine
Proactive Therapeutic Drug Monitoring to Guide
Prospective Treatment Changes Superior to No
Therapeutic Drug Monitoring?
Key message. In patients with quiescent IBD treated
with anti-TNF agents, the benefit of routine proactive TDM
over no therapeutic monitoring is uncertain (very-low-
quality evidence).Effect estimates. We did not identify any RCT or
comparative observational study evaluating the role of
routine proactive TDM for achieving remission. Therefore,
indirect evidence was derived from a single RCT—the
Trough Concentration Adapted Infliximab Treatment
(TAXIT) trial. In TAXIT, 263 responder patients (178 CD and
85 ulcerative colitis [UC]) on maintenance infliximab were
first dose optimized to reach an infliximab trough concen-
tration within the 37-mg/mL range (optimization phase).38
Once infliximab trough was within the therapeutic target
range (average of 2.1 optimizations needed), patients were
randomized to either continued TDM-guided dosing (ie,
continuous drug monitoring before each dose to stay within
target trough range, n ¼ 128) or no TDM with empiric
dosing based on symptoms and CRP (n ¼ 123) during the
maintenance phase. The duration of the maintenance phase
was 1 year after randomization and the primary end point
was defined as the proportion of patients in each group in
clinical (Harvey-Bradshaw index 4 for CD and partial
Mayo score 2 with no individual subscore >1 for UC) and
biological remission (CRP concentration of <5 mg/L).
Before the optimization phase, only 121 of 275 (44%) pa-
tients were in the predefined target trough range (37 mg/
mL), whereas 82 (30%) had a subtherapeutic trough con-
centration (<3 mg/mL) (including 24 patients with unde-
tectable trough, of which 18 were positive for ADAb).
Infliximab trough concentration was >7 mg/mL in 72 pa-
tients (26.2%). In this trial, with initial optimization, in the
subset of patients with initial low trough concentration, the
proportion of patients with CD in clinical remission
increased (pre- vs post-optimization, 28 of 43 [65%] vs 38
of 43 [88%]). However, after initial optimization, the pro-
portion of patients achieving remission at 1 year with
continued proactive routine TDM (88 of 128 [69%]) vs no
TDM (81 of 123 [66%]) (and empiric escalation in case of
clinical or biochemical relapse) was not different (RR, 1.04;
95% CI, 0.881.24) (Table 3).
Quality of evidence. The single RCT used to inform
this question provides only indirect evidence on the po-
tential role of routine proactive TDM because all patients
were in clinical response on maintenance infliximab therapy
and before randomization were “trough-optimized,” that is,
underwent proactive monitoring to achieve a therapeutic
infliximab trough between 3 and 7 mg/mL. Therefore, this
trial does not inform on the role of one-time dose optimi-
zation, infrequent optimization, or on early optimization in
patients at high risk of increased drug clearance due to
immune-mediated or nonimmune-mediated pathway. Due
to summary estimate near unity, and with very wide CIs,
very serious imprecision was noted. There was no serious
risk of bias. Therefore, the overall quality of evidence was
rated as very low.
Potential harms of intervention. Routine proactive
TDM can impose modest inconvenience and be expensive
due to repeated testing. The feasibility of such an approach
for drugs administered subcutaneously every 24 weeks is
unclear. In addition, because target thresholds are poorly
defined, inconsistent, and can vary depending on individual
patient or targeted outcome, proactive TDM may lead to
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in patients otherwise in remission. In contrast, there are
very few direct harms to patients of not performing pro-
active TDM. In the TAXIT trial, at the end of 1 year, a higher
proportion of patients randomized to no TDM developed
ADAbs and undetectable infliximab trough, which can
conceivably put patients at risk of disease flare in the
long-term.
Discussion. Unfortunately, there was no direct evi-
dence to compare the benefit and harms of routine proac-
tive TDM vs no TDM and, therefore, we relied on indirect
evidence to inform the evidence. During the optimization
phase of TAXIT, all patients underwent proactive moni-
toring to achieve investigator-defined target infliximab
concentrations, and this led to an increase in the proportion
of patients in remission (with dose escalation in the subset
of patients with infliximab trough concentrations <3 mg/mL
at screening), and allowed a 28% reduction in drug costs in
those patients with supratherapeutic drug concentrations
(>7 mg/mL) and in whom the dose was reduced safely.38
While these results suggest there might be a benefit to a
subset of patients for conducting one-time proactive TDM to
optimize infliximab therapy during maintenance phase,
there was no comparator group for this part of the study.
The randomization phase of TAXIT does inform us that, after
initial optimization, continued proactive TDM and
concentration-based dosing at every infusion, is not supe-
rior to clinically guided dosing, for achieving clinical and
biologic remission at least up to 1 year of therapy. However,
current evidence does not inform on role of one-time dose
optimization, infrequent optimization (eg, once or twice a
year) or on early optimization in patients at high risk of
increased drug clearance due to immune- or nonimmune-
mediated pathway, comparison of proactive TDM vs reactive
TDM, or the potential benefits of routine and continuous
proactive TDM over no TDM on long-term outcomes
(beyond 1 year).
In a single-center retrospective cohort study of patients
on maintenance infliximab in clinical remission, Vaughn
et al39 observed that patients who undergo proactive TDM
(n ¼ 48) are significantly more likely to remain on inflix-
imab compared with patients who do not undergo proactive
TDM (n ¼ 78) (at 5 years, 86% vs 52%; hazard ratio, 0.3;
95% CI, 0.10.6). Rates of discontinuation of infliximab
therapy due to clinical flare (0% vs 19%) or infusion reac-
tion (2% vs 7.7%) was also lower in patients undergoing
proactive TDM vs no TDM. However, there were limited
data on direct patient-relevant clinical outcomes, and the
study included a highly selected group of patients.
Post-hoc analyses of clinical trials of induction therapy
and observational studies have suggested an exposure
response relationship, with patients with higher trough
concentrations between weeks 4 and 14 more likely to
achieve remission on follow-up compared with patients
with lower trough concentrations.40–44 In a post-hoc anal-
ysis of the ACT 12 (Active Ulcerative Colitis Trials) trials,
including 242 patients with UC receiving standard inflix-
imab induction and maintenance therapy, Adedokun et al40
observed that, compared with patients with lowest quartile
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quartile were significantly more likely to achieve clinical
remission (Q1 vs Q3 vs Q4: 26.3% vs 43.9% vs 43.1%;
P < .05) and mucosal healing (45.6% vs 71.9% vs 79.3%;
P < .001). A similar exposureresponse relationship was
observed at 6 weeks, on post-hoc analyses of trials of goli-
mumab in patients with UC.45 Conceivably, there may be a
benefit of early optimization of therapy during induction
through proactive TDM. But there is a lack of prospective
interventional data assessing the value of proactive TDM
during induction to increase remission rates by targeting
threshold drug concentrations.
Threshold Trough Concentrations of
AntiLTumor Necrosis Factor Agents
The choice of therapeutic threshold drug trough con-
centration is critical to understand why patients lose
response to therapy and to guide treatment decisions. It is
important to note that target trough concentrations are not
absolute values, but rather represent a spectrum with an
exposureresponse relationship, and may vary by treat-
ment target (clinical remission vs endoscopic remission),
disease state (high disease activity vs low disease activity),
or phase of therapy (induction vs maintenance). For
example, in the study by Adedokun et al,40 the proposed
threshold for infliximab was 22.0 mg/mL (week 6), which
was associated with clinical response at week 8 compared
with thresholds of 5.1 mg/mL and 3.7 mg/mL, which were
associated with clinical response at week 14 and week 30,
respectively. Therefore, provider and patient target thresh-
olds can vary, depending on what scenario TDM is per-
formed in, and a therapeutic range is more likely rather than
a single fixed threshold. For example, when TDM is per-
formed in the reactive setting, given limited treatment op-
tions, the primary focus may be to identify above what
trough concentration threshold is a patient unlikely to
respond to further dose escalation; alternatively, in a pro-
active setting, the primary focus of TDM may be to identify
whether a patient is below a certain threshold at which risk
of failure of therapy is high.
We did not identify any RCTs or comparative studies
comparing different target trough concentration thresholds
of anti-TNF agents. We sought to evaluate the relative pro-
portion of patients who were or were not in remission,
above and below a target trough concentration. These data
were derived largely from cross-sectional studies of main-
tenance therapy, wherein studies reported the sensitivity
and specificity of one or more different thresholds in pre-
dicting the presence of clinical remission (or response).
Most often, these data were reported as the value corre-
sponding to the maximum area under the receiver-operator
curve. To compare performance of different thresholds, we
sought unpublished data from authors on performance of
prespecified commonly used thresholds. We could report
such data from infliximab, adalimumab, certolizumab pegol,
and golimumab; there were very limited data on relative
performance of different maintenance troughs for vedoli-
zumab or ustekinumab.Infliximab Trough Concentration Thresholds
Data on relative performance of different infliximab
trough concentration thresholds was derived from 6 studies,
which either reported or shared unpublished data for mul-
tiple predefined trough thresholds (Table 4).40,41,4649 On
analysis of different thresholds, proportion of patients not in
remission progressively decreased from 25% when using an
infliximab threshold of 1 mg/mL, to 15% with an inflix-
imab trough concentration of 3 mg/mL, 8% with an
infliximab trough concentration of 5 mg/mL and 4% with
an infliximab trough concentration of 7 mg/mL or 10 mg/
mL (P < .001). Therefore, with increasing trough concen-
tration thresholds of 7 mg/mL or 10 mg/mL, the
proportion of infliximab-treated patients not in remission
was not significantly different. In contrast, we observed that
at higher infliximab trough concentration thresholds, a sig-
nificant proportion of patients even below that threshold
were in remission. Interestingly, when comparing the pro-
portion of patients not in remission above a certain
threshold for UC and CD separately, higher numbers of
patients with UC were unlikely to be in remission at inflix-
imab trough concentrations 3 mg/mL compared with pa-
tients with CD (Supplementary Table 3). However, only a
small proportion of patients are not in clinical remission
with an infliximab trough concentration 7 mg/mL,
regardless of disease type.
Therefore, at an infliximab trough concentration of 5
mg/mL during maintenance therapy, a small proportion of
patients may not be in remission. Based on indirect evi-
dence, there may be benefit to targeting higher trough
concentrations in patients who are not responding at lower
trough concentrations, although there may be only marginal
benefit for targeting infliximab trough concentrations of 7
mg/mL for achieving clinical remission. Although a formal
GRADE-based analysis of this evidence was not conducted,
the included studies were at high risk of bias due to selec-
tive inclusion of patients. Inconsistency was observed across
studies in trough thresholds and, therefore, we relied on
unpublished data across prespecified thresholds. Also, due
to paucity of direct evidence, indirect evidence from cross-
sectional studies is being used to extrapolate to potential
benefits of escalation of therapy.Adalimumab Trough Concentration Thresholds
Data on relative performance of different adalimumab
trough concentration thresholds was derived from 6 studies
that either reported or shared unpublished data for multiple
thresholds (Table 5).25,5054 Of note, if studies did not
report outcomes at multiple trough concentration, we used
a cutoff for which data were reported for pooling. On
analysis of different thresholds, proportion of patients not in
remission progressively decreased from 17% when using an
adalimumab threshold 5.0 ± 1 mg/mL, to 10% with an
adalimumab trough concentration of 7.5 ± 1 mg/mL. In
contrast, we observed that at higher adalimumab trough
concentration thresholds, a significant proportion of pa-
tients even below that threshold were in remission. There
were limited data on analyzing differences in thresholds
Table 4.Distribution of Patients in Terms of Clinical Status, at Different Infliximab Cutoffs in Cross-Sectional or Cohort Studies
Infliximab
cutoff, mg/mL
Studies, n/
patients, n
Trough at or above cutoff, % (95% CI) Trough below cutoff, % (95% CI)
Patients in
remission
Patients not in
remissiona
Patients in
remission
Patients not in
remission
1 640,41,46–49/929 49.2 (38.859.6) 24.8 (17.733.7) 9.5 (6.014.6) 15.5 (10.921.7)
3 6,40,41,46–49/929 36.7 (28.645.7) 14.7 (9.721.7) 20.7 (14.029.5) 25.9 (20.831.7)
5 640,41,46–49/929 27.3 (20.934.9) 7.9 (4.613.2) 29.7 (19.941.8) 32.8 (25.840.7)
7 540,46–49/726 21.4 (15.129.5) 3.9 (1.59.5) 36.0 (24.349.6) 36.4 (25.948.3)
10 440,41,47,48/772 17.2 (11.824.6) 4.3 (1.89.6) 43.0 (27.659.8) 35.7 (27.145.4)
NOTE. The proportion of patients not in remission above infliximab trough concentration thresholds decreases with increasing
trough concentration.
aP value for trend, for this group (most relevant) <.001.
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centration of 7.5 mg/mL during maintenance therapy, a
small proportion of patients may not be in remission. Based
on indirect evidence, there may be benefit to targeting
higher trough concentrations in patients who are not
responding at lower trough concentrations.Certolizumab Pegol Trough Concentration
Thresholds
For certolizumab pegol maintenance therapy, we
included data from a large exposureresponse pooled
analysis, including data from 9 trials encompassing 2157
patients (Table 6).55 When focusing on the quadrant with
certolizumab pegol trough concentration greater than or
equal to the threshold and proportion of patients not in
remission, a similar trend was apparent as for infliximab
and adalimumab. Of the patients with a certolizumab pegol
trough concentration of 10 mg/mL, 42% are not in
remission compared with 32% with a certolizumab pegol
trough concentration of 15 mg/mL and 26% with a cer-
tolizumab pegol trough concentration of 20 mg/mL.
Therefore, targeting a certolizumab pegol trough concen-
tration of 20 mg/mL can lead to an increased proportion of
patients in clinical remission, with some patients benefiting
from higher concentrations. In comparison to infliximab and
adalimumab, certolizumab pegol concentration thresholds
were considerably higher and so was the proportion of
patients not in remission at those thresholds.Table 5.Distribution of Patients in Terms of Clinical Status, at D
Cohort Studies
Adalimumab
cutoff, mg/mL
Studies, n/
patients, n
Trough at or above cuto
Patients in
remission
5.0 ± 1 425,5052/232 39.3 (6.354.0)
7.5 ± 1 352–54/131 46.8 (34.859.2)
NOTE. The proportion of patients not in remission above ad
increasing trough concentration.
aP value for trend, for this group (most relevant) <.001.Golimumab Trough Concentration Thresholds
Exposureresponse data on golimumab is sparse
compared with other anti-TNF agents. In a post-hoc analysis
of the PURSUIT (Program of Ulcerative Colitis Research
Studies Utilizing an Investigational Treatment) trials, Ade-
dokun et al45 identified a golimumab concentration of 2.5
mg/mL at week 6 during induction and 1.4 mg/mL at week
44 (steady-state trough concentration) during the mainte-
nance phase to be minimal thresholds to achieve clinically
important outcomes (sensitivity 59.0%, specificity 67.2%
and sensitivity 54.1%, specificity 77.6%, respectively). In a
prospective observational study of 21 patients with UC,
Detrez et al56 identified a golimumab threshold concentra-
tion of 2.6 mg/mL at week 6 to be associated with a clinical
improvement at week 14 (90% specificity, 56% sensitivity,
area under receiver-operator characteristic curve, 0.79;
P ¼ .034).
Discussion. In summary, when using reactive TDM
during maintenance therapy, a trough concentration
threshold of 5 mg/mL for infliximab, 7.5 mg/mL for
adalimumab, and 20 mg/mL for certolizumab pegol, may
identify most patients who are unlikely to respond to
escalation of therapy. However, a small proportion of pa-
tients with ongoing inflammation despite adequate trough
concentrations may be able to achieve clinical remission by
targeting higher drug trough concentrations. In addition,
these thresholds may be different between UC and CD, and
patients with UC may require higher target trough concen-
trations compared with CD. These target trough thresholdsifferent Adalimumab Cutoffs in Cross-Sectional or
ff, % (95% CI) Trough below cutoff, % (95% CI)
Patients not
in remissiona
Patients in
remission
Patients not in
remission
17.0 (12.722.5) 11.3 (7.716.2) 34.6 (25.245.3)
10.3 (6.116.9) 21.4 (15.229.3) 23.3 (16.831.4)
alimumab trough concentration thresholds decreases with
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Table 6.Distribution of Patients in Terms of Clinical Status, at Different Certolizumab Pegol Cutoffs in a Pooled Analysis of
Individual Participant Data of 9 Trials (2157 Patients) of Certolizumab Pegol in Crohn’s Disease
Certolizumab pegol
cutoff, mg/mL
Trough at or above cutoff, % (n) Trough below cutoff, % (n)
Patients in
remission
Patients not in
remissiona
Patients in
remission
Patients not in
remission
10 21.3 (231) 41.6 (450) 11.6 (125) 25.5 (276)
15 16.6 (180) 32.2 (348) 16.3 (176) 34.9 (378)
20 12.9 (140) 25.5 (276) 20.0 (216) 41.6 (450)
NOTE. The proportion of patients not in remission above certolizumab pegol trough concentration thresholds decreases with
increasing trough concentration.
aP value for trend, for this group (most relevant) <.001.
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scopic remission, rather than clinical response/remission.
Although there are emerging data on optimal golimumab
trough concentrations, the data are too sparse to allow for
comprehensive assessment of different reported thresholds.Thresholds for Anti-Drug Antibodies to
AntiLTumor Necrosis Factor Agents
In contrast to trough concentrations, quantitative results
of ADAbs from different assays cannot be compared, and are
typically interpreted qualitatively in the appropriate clinical
context. Some studies have shown that patients with low-
level ADAbs with detectable but subtherapeutic trough
might still respond to escalation compared with patients
with high-level ADAbs.57–59 In a cohort study of 125 pa-
tients with CD by Baert et al,60 an ADAb concentration of >8
mg/mL was considered “high” and correlated with a shorter
duration of response in between infusions and a higher
risk of infusion reactions (RR, 2.40; 95% CI, 1.653.66;
P < .001).
In a retrospective cohort study, it was observed that of
the patients developing ADAbs to infliximab, 15 of 53 (28%)
had transient ADAbs, and 38 of 53 (72%) had sustained
ADAbs.57 A similar proportion of patients lost response to
therapy during follow-up in both groups, 13 of 15 (87%)
and 30 of 38 (79%) patients, respectively. However, of those
patients undergoing empiric infliximab dose escalation at
time of loss of response, 69% of patients with transient
ADAbs recaptured response compared with 16% of patients
with sustained ADAbs (P ¼ .0028). A concentration of
ADAbs to infliximab of >9.1 U/mL was associated with an
unsuccessful intervention (likelihood ratio, 3.6; specificity
82%, sensitivity 65%, area under the curve, 0.73; P ¼ .003).
Of those patients with transient ADAbs, 2 of 15 (13%) had
to discontinue infliximab therapy because of persistent loss
of response or hypersensitivity reactions compared with 26
of 38 (68%) with sustained ADAbs (RR, 5.1; 95% CI,
1.419.0; P < .001). In addition, in the retrospective study
of Yanai et al,24 a threshold for ADAbs to infliximab of
>9 mg/mL equivalents and for ADAbs to adalimumab of
>4 mg/mL was proposed that identified patients with highADAbs that did not respond to empiric dose escalation with
90% specificity.Primer on Therapeutic Drug Monitoring
for Thiopurines
Thiopurine metabolism is complex and involves multiple
conversion steps. Azathioprine (AZA) is a prodrug and
enzymatic and nonenzymatic conjugation via glutathione is
necessary to convert it into 6-mercaptopurine (6-MP).61,62
Several enzymes are involved in modification of 6-MP into
active (6-TGN) and inactive (6-MMP, 6-
methylmercaptopurine ribonucleotides, thiouric acid) me-
tabolites. The immunosuppressive effect of thiopurines is
achieved by incorporation of 6-TGN into nucleic acids
instead of guanine nucleotides, which inhibits purine and
protein synthesis in lymphocytes. TPMT is one of the key
enzymes in thiopurine metabolism. In patients with low or
absent TPMT enzyme activity, thiopurine exposure can lead
to severe bone marrow toxicity due to the excess production
of drug-derived TGN metabolites.
TPMT enzyme activity is controlled by >25 genetic
polymorphisms, but the most common 4 alleles are found in
80%95% of tested persons.63 Approximately 4%11% of
the population are heterozygous for a variant TPMT allele
and have intermediate enzyme activity, and around 0.3%
are homozygous and have very low or absent enzyme ac-
tivity.63 TPMT activity has been associated with risk of
myelosuppression, but not other adverse events, in
thiopurine-treated patients. In a recent systematic review of
54 observational studies and 1 randomized trial of TPMT
status in adults and children with inflammatory diseases,
the odds of thiopurine-induced leukopenia for heterozygous
and homozygous genotypes was 4.3 (95% CI, 2.76.9) and
20.8 (95% CI, 3.4126.9), respectively.63 Most events of
leukopenia occur within 8 weeks of starting therapy, how-
ever, leukopenia can be observed after many months of
thiopurine therapy.64,65 Based on risk of myelosuppression
in patients with low or absent TPMT enzyme activity, the
Food and Drug Administration recommends genotype or
phenotype testing before high-dose chemotherapy with
thiopurines in pediatric patients.66
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with the level of active 6-TGN metabolites, and hepatotox-
icity has been associated with higher levels of the inactive
metabolites 6-MMP and 6-methylmercaptopurine ribonu-
cleotides.5,67,68 TDM of thiopurines may offer the possibility
to improve patient outcomes by identifying symptomatic
patients with low 6-TGN levels. Additionally, by measuring
6-MMP levels, a subgroup of patients can be identified who
preferentially convert 6-MP to 6-MMP and often do not
achieve sufficient 6-TGN levels. This group of patients, often
described as “shunters,” may be susceptible to hepatotox-
icity because thiopurine dose escalation leads to 6-MMP
accumulation.AG
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Question 3: In Patients With Inflammatory Bowel
Disease Being Started on Thiopurines, Is Routine
Thiopurine Methyltransferase Measurement (to
Guide Dosing) Superior to No Thiopurine
Methyltransferase Measurement (With Empiric
Weight-Based Dosing of Thiopurines)?
Key message. The benefit of routine TPMT testing (to
guide initial dosing of thiopurines) over no TPMT testing
(with empiric weight-based dosing) is uncertain for most
patients, but may avoid serious harm in a small fraction of
patients (low-quality evidence).
Effect estimates. Three RCTs comparing a strategy of
TPMT testing (to guide thiopurine dosing) vs no TPMT
testing (with empiric weight-based thiopurine dosing) were
identified.69–71 In the intervention arm, thiopurine dose
recommendations were based on TPMT genotype (2 trials)
or enzyme activity (1 trial), such that patients with wild-
type genotype (or normal enzyme activity) were advised
to start 22.5 mg/kg/d AZA (or 11.5 mg/kg/d 6-MP);
patients heterozygous for TPMT genotype (or with inter-
mediate enzyme activity) were advised to start at lower
doses (50% dose reduction), and patients homozygous for
TPMT genotype (or with low/absent enzyme activity) were
either advised to avoid thiopurines or started at 010% of
standard dose. In contrast, patients in the control arms of
these trials were advised to start standard weight-based
dose of thiopurines upfront (2 trials) or with gradual
titration (1 trial); regardless of intervention, biochemical
parameters, including complete blood count and liver en-
zymes, were closely monitored in both treatment arms.
Among 1145 patients included in trials, 1032 (90.1%)
had wild-type genotype (or normal enzyme activity), 111
patients (9.7%) were heterozygous, and 2 patients (0.17%)
were homozygous. None of the trials reported rates of
serious adverse events; hematologic adverse events, pri-
marily neutropenia, and treatment discontinuation, were
considered surrogates for outcome of interest. Observed
rates of hematologic adverse events (TPMT testing vs no
TPMT testing: 32 of 582 vs 32 of 552; RR, 0.94; 95% CI,
0.591.50) and treatment discontinuation (225 of 582 vs
195 of 552; RR, 1.09; 95% CI, 0.941.27) were not signif-
icantly different between the treatment groups (Table 7);rates of other adverse events like pancreatitis or hepato-
toxicity were also not significantly different. Six patients
died in 2 trials, including 2 patients with sepsis-related
deaths (1 in each arm); the other 4 deaths were deemed
unrelated to AZA (RR, 0.48; 95% CI, 0.092.62). No signif-
icant difference was observed in rates of clinical remission
between treatment arms, in a subset of patients with
baseline active symptoms (RR, 1.03; 95% CI, 0.841.27), or
in mean disease activity scores.
Quality of evidence
Overall, the trials were deemed to be at low risk of
bias; though physicians were not aware of TPMT genotype
status, true blinding was not feasible because treatment
advice on choice of thiopurine starting dose allowed
inference of TPMT genotype in the intervention arm.
While TPMT enzyme activity is more commonly available
and used in clinical practice in the United States, TPMT
genotype testing correlates closely with TPMT enzyme
activity levels and, therefore, interventions were deemed
comparable across trials63; in addition, although trials
presented events based on genotype, results for TPMT
enzyme activity were reported to be similar. Because in-
formation on serious adverse events was not reported
directly, hematologic adverse events and treatment
discontinuation were deemed surrogate outcomes and
evidence was rated down for indirectness. Evidence was
also rated down for serious imprecision due to a wide CI
crossing unity. The overall quality of evidence was rated
as low, that is, there was low confidence in the effect es-
timates supporting the use of routine TPMT testing (to
guide thiopurine dosing) over no TPMT testing (with
empiric weight-based dosing) in reducing risk of serious
adverse events.
Potential harms of intervention. There is minimal
risk to performing TPMT genotype or enzyme activity as a
blood test. While testing for TPMT may potentially delay
starting therapy for approximately 12 weeks (while
awaiting test results), it is likely inconsequential given the
slow onset of action of this medication. TPMT testing neither
increases nor alleviates the burden of routine laboratory
monitoring needed for patients treated with thiopurines
because laboratory monitoring is obligatory for all
thiopurine-treated patients, regardless of TPMT status. On
the other hand, for a very small fraction of patients who
have very low or absent enzyme activity, no TPMT testing
with empiric weight-based dosing of thiopurines can
conceivably result in early and severe leukopenia and
associated complications before the first scheduled labora-
tory monitoring.
Discussion. TPMT activity can be evaluated by either
genotyping or directly measuring the TPMT activity in red
blood cells by radiochemical or chromatographic techniques
in vitro (phenotyping).62 For this review, we did not eval-
uate the different methodologies used to determine TPMT
activity. There is an ongoing debate about the advantages
and disadvantages of a genotyping vs phenotyping
approach, which is discussed in depth in other publica-
tions.63,72 It is important to note that blood transfusions in a
Table 7. In Patients With Inflammatory Bowel Disease Being Started on Thiopurines, Is Routine Thiopurine Methyltransferase Enzyme Activity Or Genotype Measurement
(to Guide Dosing) Superior to No Thiopurine Methyltransferase Measurement (With Empiric Weight-Based Dosing of Thiopurines)?69–71
No. of
participants
(studies),
follow-up
Quality assessment Summary of findings
Risk of
bias Inconsistency Indirectness Imprecision
Publication
bias
Overall quality
of evidence
Study event rate,
n (%)
Relative effect,
RR (95% CI)
Anticipated absolute
effects
With no
TPMT
testing
With
TPMT
testing
Risk with no
TPMT testing
Risk
difference
with TPMT
testing
Discontinuation of
therapy (critical
outcome)
1134 (3 RCTs) Not serious Not serious Seriousa Seriousb None 44
Low
195/552
(35.3)
225/582
(38.7)
1.09
(0.941.27)
353 per
1000
32 more per
1000 (21
fewer to
95 more)
Hematologic
adverse events
(critical outcome)
1134 (3 RCTs) Not serious Not serious Seriousa Seriousb None 44
Low
32/552
(5.8)
32/582
(5.5)
0.94
(0.591.50)
58 per
1000
3 fewer per
1000 (24
fewer to
29 more)
RR, risk ratio.
aSurrogate outcomes for critical outcome of interest (serious adverse events).
bWide CIs crossing unity, and unable to exclude high rate of benefit or harm.
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affect the analyses and yield unreliable results.
Despite observational studies reporting significantly
higher risk of myelosuppression in a subset of patients
treated with thiopurines, the quality of evidence supporting
routine TPMT testing to guide thiopurine dosing was
deemed low based on RCTs. This can be attributed to 2
factors. First, the frequency of heterozygous (9.7%) and
homozygous (0.17%) genotype in included trials is low,
comparable to the general population. Coenen et al69 per-
formed a post-hoc subgroup analysis of their large Dutch
trial and demonstrated a significant benefit of TPMT pre-
testing for the heterozygous carriers with 89% risk reduc-
tion (RR, 0.11; 95% CI, 0.010.85) for hematologic adverse
events. Based on these data, they calculated that a pro-
spective trial would need more than 42,000 participants to
show a significant benefit for the whole patient population.
Second, a significant proportion of thiopurine-related he-
matologic adverse events occur despite normal TPMT sta-
tus, emphasizing that TPMT testing cannot substitute for
routine complete blood count (CBC) monitoring in patients
receiving thiopurines.64,73 The package insert for AZA rec-
ommends monitoring of CBC weekly during the first month,
twice monthly for the second and third months of treatment,
then monthly or more frequently if dosage alterations or
other therapy changes are necessary. However, patient and
physician compliance with regular CBC monitoring is sub-
optimal; in a cohort study, the median completion of CBC
monitoring in the first 8 weeks and between weeks 9 and 26
of therapy was 3 CBCs (interquartile range, 14) and 1
CBCs (interquartile range, 12), respectively.65 Although
routine laboratory monitoring is necessary with thiopurine
use in IBD patients, the optimal frequency of monitoring is
uncertain.74
Given the low prevalence of heterozygous and homozy-
gous TPMT genotypes, the magnitude of population-level
benefit of routine TPMT testing is likely to be very small.
However, there is minimal risk to performing this test, and it
neither increases nor alleviates the potential burden of
routine laboratory monitoring needed for patients treated
with thiopurines. Contemporary cost-effectiveness analyses
of routine TPMT testing are lacking. In a cost-effectiveness
analysis based on the UK TARGET trial, there were mar-
ginal cost-savings, but these results may not apply to the
United States because costs of TPMT testing vary signifi-
cantly across health care systems.75AG
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Bowel Disease Treated With Thiopurines or With
Side Effects Thought to be Due to Thiopurine
Toxicity, Is Reactive Therapeutic Drug Monitoring
to Guide Treatment Changes Superior to No
Therapeutic Drug Monitoring With Empiric
Treatment Changes?
Key message. In patients with IBD treated with thio-
purines with active IBD-related symptoms or side effects
thought to be due to thiopurine toxicity, there may be abenefit of reactive TDM to guide treatment changes over
empiric treatment changes (very-low-quality evidence).
Effect estimates. We did not identify any randomized
trials or prospective comparative studies in thiopurine-
treated IBD patients comparing reactive TDM to guide
treatment changes vs empiric treatment changes. One
retrospective single-group observational study reported
outcomes in thiopurine-treated symptomatic IBD patients
when treatment changes were concordant vs discordant
with suggestions based on a reactive TDM management al-
gorithm (Supplementary Table 4).76 Based on this algo-
rithm, 25 of 63 patients were considered refractory to
thiopurine therapy despite appropriate dosing (6-TGN,
230450 pmol/8  108 RBCs; normal or high 6-MMP), 18
were underdosed (6-TGN <230 pmol/8  108 RBCs, normal
6-MMP), 6 were noncompliant, 8 were overdosed (6-TGN
>450 pmol/8  108 RBCs), and 6 patients were consid-
ered shunters (low 6-TGN, high 6-MMP, with 6-MMP/6TGN
ratio >11). Among patients deemed refractory to thiopurine
therapy based on TDM algorithm, 12 of 12 patients (100%)
in whom treatment changes were concordant with sugges-
tions from algorithm (switching to alternative therapy,
without further dose escalation) improved, and only 1 of 13
patients (7.7%) improved when treatment changes were
discordant from suggested algorithm; of 4 patients in whom
thiopurine dose was increased despite “therapeutic” levels,
3 failed to respond and 1 developed toxicity. Among
underdosed patients, 13 of 15 patients (86.7%) with
algorithm-concordant dose escalation achieved clinical
response; treatment discordance in the form of failure to
increase dose resulted in failure to achieve clinical response
(1 of 1), whereas addition of alternative therapy like ste-
roids or anti-TNF could achieve response in 2 patients. Of 7
patients deemed to be failing thiopurines despite supra-
therapeutic 6-TGN levels, algorithm-concordant switching to
alternative therapy with or without decrease in thiopurine
dose resulted in clinical response in 5 of 5 patients (100%),
and 2 patients in whom thiopurine dose was decreased or
unchanged without any associated treatment changes failed
to respond. Among 6-MMP shunters, a decrease in thio-
purine dose with either addition of allopurinol or other
alternative therapies, concordant with management algo-
rithm resulted in clinical response in 4 of 4 patients (100%),
and only a decrease in thiopurine dose did not result in
clinical improvement in 2 of 2 patients (although abnormal
liver enzymes resolved). Based on this single study,
considerable differences were observed in patient outcomes
if treatment decisions were concordant with the proposed
metabolite-based algorithm compared with empiric treat-
ment changes, a proportion of which may be discordant
with algorithm. Overall, algorithm-concordant treatment
changes were significantly more likely to result in clinical
response in symptomatic patients compared with
algorithm-discordant treatment changes (36 of 42 vs 3 of
18; RR, 5.15; 95% CI, 1.8214.56) (Table 8).
Quality of evidence. Due to the observational nature
of the study, with inherent risk of bias of unmeasured
confounding, along with indirectness of comparisons
(instead of directly comparing reactive TDM vs empiric
850 Vande Casteele et al Gastroenterology Vol. 153, No. 3
AGA
SECTIONtreatment changes, the study compared results for algo-
rithm concordant vs discordant treatment decisions) and
imprecision due to small study size, overall quality of evi-
dence was rated as very low quality, that is, there was very
low confidence in the effect estimates supporting the use of
reactive TDM (to guide thiopurine dosing) over empiric
treatment changes in thiopurine-treated patients with
inadequate clinical response or side effects.
Potential harms of intervention. TDM is performed
through a blood test in patients on a stable dose of thio-
purines and can cause mild inconvenience. The performance
of therapeutic 6-TGN cutoffs is suboptimal in discriminating
those who may or may not respond to specific treatment
changes; in addition, target 6-TGN cutoffs when thiopurines
are used as concomitant therapy with biologics to decrease
risk of immunogenicity are poorly defined. Incidental find-
ings during thiopurine metabolite testing can potentially
result in unwarranted treatment changes. With the avail-
ability of several newer and more effective therapeutic
agents over the last decade, attempts at close metabolite
monitoring and serial dose adjustments can potentially
delay more effective therapy in a subset of underdosed
patients who may be inherently thiopurine-resistant.
In contrast, empiric treatment changes, such as escala-
tion of therapy in patients with suboptimal response, may
result in excessively high 6-TGN level, which increases risk
of leukopenia, or excessively high 6-MMP levels due to
shunting, which increases risk of hepatotoxicity. Inappro-
priate treatment changes can also potentially delay use of
more effective therapy.
Discussion. Reactive drug monitoring in patients with
active symptoms or drug-related side effects assumes that
adaption of a drug level to a suggested drug concentrations
results in a significant improvement or disappearance of the
side effect. However, the performance of the most
commonly used 6-TGN cutoff (>230 pmol/8  108 RBCs) is
suboptimal (see discussion of routine thiopurine TDM).
Additionally, when applying these cutoffs to reactive TDM,
there is potential risk of bias because most studies evalu-
ating this cutoff were cross-sectional and lacked standard-
ization of nucleotide assays. There is paucity of prospective
studies evaluating whether achieving proposed target 6-
TGN levels would be associated with higher rates of clin-
ical remission. Available evidence does not inform whether
these proposed cutoffs might be different in patients with
CD and UC. It is unclear whether optimal cutoffs of 6-TGN
may be different in patients on thiopurine monotherapy
(where the goal is controlling disease activity) and patients
in whom thiopurines are used in conjunction with anti-TNF
agents or other biologic agents (where the primary goal may
be to decrease immunogenicity). In a cross-sectional study,
Yarur et al77 observed a moderate correlation between 6-
TGN levels and anti-TNF levels, and a 6-TGN cutoff >125
pmol/8  108 RBCs was associated with high anti-TNF and
mucosal healing compared with patients with 6-TGN <125
pmol/8  108 RBCs. While anti-TNF level was numerically
higher in patients with 6-TGN >252 pmol/8  108 RBCs
compared with patients with 6-TGN 125176 pmol/8 
108 RBCs (17.8 mg/mL vs 13.4 mg/mL), this difference wasnot statistically significant (P ¼ .12). However, in another
cross-sectional study, there was no correlation between
6-TGN levels and anti-TNF levels, with limited ability of 6-
TGN >125 pmol/8  108 RBCs to discriminate achieve-
ment of adequate vs inadequate trough levels (unpublished
data, personal communication with Viraj Kariyawasam,
Mark Ward, and Peter Irving).
Two studies laid the foundation for reactive TDM for
thiopurines showing that an increase of thiopurine dosing in
a subgroup of patients with active IBD was associated with a
significant increase of 6-TGN concentrations and clinical
remission.5,78 However, in both studies, the dose adaptation
in the individual patient was not performed based on trough
levels, but solely on clinical judgment, and specific cutoffs
were derived retroactively. Many patients in both studies
were not dosed according to the recommended weight-
based algorithm (22.5 mg/kg body weight for AZA and
11.5 mg/kg body weight for 6-MP). Dubinsky et al5 also
observed that in some patients, thiopurine dose increase
resulted mainly in a shunting of thiopurine metabolism to-
ward 6-MMP rather than 6-TGN, and these patients failed to
achieve remission but rather developed hepatotoxicity in
the presence of high 6-MMP levels. Four noncomparative,
retrospective studies have reported the efficacy of reactive
TDM, which had been initiated in thiopurine-treated pa-
tients because of active IBD despite thiopurine therapy,
suspicion of lack of adherence, or adverse events thought to
be related to thiopurine therapy.79–82 The end points for the
evaluation of a successful reactive TDM in the individual
patients in these studies varied and included change in
disease management (adaption of drug dosing, switch to
another drug, or surgery), improved clinical outcome or
remission based on physician assessment or resolution of
side effects thought to be thiopurine related; however, none
of these studies reported outcomes with empiric treatment
changes and did not contribute to summary estimates. None
of the studies used established diseases activity scores, such
as the Mayo or the Harvey Bradshaw score, or assessed for
mucosal healing. The outcomes are depicted in
Supplementary Table 5. Of note, noncompliance occurred in
these retrospective studies in 6%11%.76,82 Overall, the
data suggest that in more than half of the patients, adoption
of the therapeutic approach based on trough levels was
successful in achieving a better outcome, defined as either
response or remission, and that in more than one third of
patients, a resolution of the thiopurine-associated side
effects could be accomplished.Question 5. In Patients With Inflammatory Bowel
Disease Treated With Thiopurines, Is Routine
Therapeutic Drug Monitoring to Guide
Thiopurine Dosing Superior to Empiric
Weight-Based Dosing?
Key message. The benefit of routine TDM to guide
thiopurine dosing over empiric weight-based dosing is un-
certain (very-low-quality evidence).
Effect estimates. Two small, randomized studies, one
double-blind RCT in the United States, another open-label
Table 8. In Patients With Active Inflammatory Bowel Disease Treated With Thiopurines or With Side Effects Thought to Be Due to Thiopurine Toxicity, Is Reactive
Therapeutic Drug Monitoring to Guide Treatment Changes Superior to no Therapeutic Drug Monitoring With Empiric Treatment Changes?76
No. of
participants
(studies),
follow-up
Quality assessment Summary of findings
Risk of
bias Inconsistency Indirectness Imprecision
Publication
bias
Overall quality
of evidence
Study event rates,
n (%)
Relative effect,
RR (95% CI)
Anticipated absolute effects
With empiric
treatment
changes
With reactive
TDM-guided
treatment
changes
Risk with
empiric
treatment
changes
Risk difference
with reactive
TDM-guided
treatment
changes
Clinical response
(critical
outcome)
60 (1 study) Not serious Not serious Seriousa Seriousb ND 4
Very low
3/18
(16.7)
36/42
(85.7)
5.15
(1.8214.56)
167 per
1,000
692 more per
1000 (137
more to
2260 more)
ND, not detected; RR, risk ratio.
aOutcomes reported based on algorithm-concordant care vs algorithm discordant care, and not empiric treatment changes; this may potentially overestimate benefit of
intervention.
bSmall study size with low event rate (optimal information size not met).
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SECTIONrandomized trial conducted in Germany, investigated
scheduled thiopurine metabolite testing with successive
adaptation of AZA therapy to a target 6-TGN concentration
of 250400 pmol/8  108 RBCs vs standard AZA weight-
based dosing (2.5 mg/kg body weight).83,84 In the US trial,
the intervention involved both TPMT testing to guide initial
dosing, followed by prospective 6-TGNguided dose adap-
tation compared with empiric weight-based dosing with
gradual dose escalation if well tolerated (regardless of
TPMT activity) in control arm.83 In contrast, in the German
trial, all patients were started on TPMT-levelguided dosing
initially, followed by randomization to 6-TGNguided dose
adaptation or continued weight-based dosing.84 On pooled
analysis of both trials, at 16 weeks there was a numerically
higher proportion of patients achieving clinical remission in
patients who underwent routine TDM-guided dose adapta-
tion compared with standard weight-based dosing (21 of 50
[42%] vs 18 of 57 [31.6%]), but the difference was not
statistically significant (RR, 1.44; 95% CI, 0.593.52)
(Table 9). The rate of serious adverse events (requiring
discontinuation of therapy) was comparable between the 2
arms (TDM-guided dose adaptation vs empiric dosing: 16 of
50 [32.0%] vs 15 of 57 [26.3%]; RR, 1.20; 95% CI,
0.502.91).
Quality of evidence. Both studies were terminated
early due to slow recruitment and failure to meet pre-
specified enrollment targets, putting them at high risk of
bias. Additionally, there was high attrition rate in both trials
(33%46%), although the analyses were conducted in
intention-to-treat manner with worst-case scenario impu-
tation. Due to the small number of events and wide CIs
crossing unity for both critical outcomes, evidence was
further rated down for very serious imprecision. The overall
quality of evidence was rated as very low quality, that is,
there was very low confidence in the effect estimates sup-
porting the use of routine TDM-guided dose adaptation over
weight-based thiopurine dosing for improving clinical
outcomes.
Potential harms of intervention. Routine moni-
toring of thiopurine metabolites is conducted through a
blood test, which imposes minimal risk to the patients.
However, with each dose adaptation, intensified laboratory
monitoring is required for early identification of neu-
tropenia or hepatotoxicity, which can be inconvenient and
expensive. Given slow onset of action of this medication,
adaptation is conducted slowly over weeks, which can
potentially delay administration of alternative effective
therapies in patients with inadequate response to
thiopurines.
Discussion. Based on 2 small RCTs at high risk of bias,
there is uncertainty whether routine 6-TGN measurement
and adaptive dosing are superior to standard weight-based
dosing based on TPMT levels. The included trials focused on
utility of trying to identify potentially underdosed patients
(6-TGN <230 pmol/8  108 RBCs), and then trying to adapt
thiopurine dosing to achieve 6-TGN level >230 pmol/8 
108 RBCs. It is important to note that although this 6-TGN
target >230 pmol/8  108 RBCs is often cited, the perfor-
mance characteristics of this cutoff are suboptimal. In arecent meta-analysis of 17 studies in 2052 patients with IBD
(12 adult and 5 pediatric IBD cohorts), 15 were designed as
cross-sectional studies, evaluating distribution of 6-TGN
levels in patients in varying stages of disease activity; only
2 studies were prospective cohort studies evaluating the
longitudinal impact of 6-TGN >230 pmol/8  108 RBCs on
disease activity.68 In these studies, 53.6% of patients were
in clinical remission at the time of 6-TGN measurement. The
overall sensitivity and specificity of 6-TGN >230 pmol/8 
108 RBCs in identifying patients in remission was 63% and
53%, respectively (area under receiver-operator character-
istic curve, 0.63). Among patients with active disease, 66%
had 6-TGN <230 pmol/8  108 RBCs and 34% had 6-TGN
>230 pmol/8  108 RBCs; however, in patients in remis-
sion, 50% patients had 6-TGN >230 pmol/8  108 RBCs
and 50% patients had 6-TGN <230 pmol/8  108 RBCs.
Patients with 6-TGN >230 pmol/8  108 RBCs were 1.4
times more likely to be in clinical remission (RR, 1.36; 95%
CI, 1.161.61) compared with patients with 6-TGN <230
pmol/8  108 RBCs, with considerable heterogeneity. It is
frequently perceived that in patients with low 6-TGN levels,
with increase in dose, a proportion of these patients might
achieve higher 6-TGN levels. However, in both randomized
studies, only a small proportion of patients in the inter-
vention arm actually achieved the target 6-TGN, despite
attempts at dose adaptation. In the US trial, despite signif-
icantly higher azathioprine dose at week 16 in the inter-
vention arm (median dose of AZA, 3.4 vs 2.3 mg/kg/d in the
individualized and weight-based dosing arms, respectively;
P < .01), there was no significant difference in 6-TGN levels
of 6-TGN concentrations (median, 197 pmol/8  108 RBCs;
range, 81286 pmol/8  108 RBCs vs median, 150 pmol/
8  108 RBCs; range, 81297 pmol/8  108 RBCs) in the
individualized and weight-based dosing arms, respectively
(P ¼ NS).83 This may be related to a change in metabolism
of AZA away from active 6-TGN metabolites toward inactive
metabolites, such as 6-MMP with dose increase.5,85 In both
trials, due to safety concerns only a limited increase in AZA
dose was allowed as a strategy to achieve the target 6-TGN
level (maximal dose limit set at 3 mg/kg AZA in the German
study and 4 mg/kg in the US study); interventions, such as
adding allopurinol to modify thiopurine metabolism pref-
erentially toward 6-TGN, were not allowed.
There were several limitations of trial design, which
failed to fully elucidate the potential benefit of routine thi-
opurine metabolite monitoring. Besides identifying under-
dosed patients (low 6-TGN level, normal 6-MMP levels),
knowledge of thiopurine metabolites can facilitate the
identification of the following subgroups: noncompliant
patients (absent/very low 6-TGN and absent/very low 6-
MMP), preferential 6-MMP producers/shunters (low 6-
TGN levels, with high 6-MMP levels), treatment refractory
patients (therapeutic 6-TGN with normal 6-MMP) or pa-
tients with high drug levels at risk of toxicity (high 6-TGN
and high 6-MMP levels). While in clinical practice, it is
conceivable that practitioners may adopt different strategies
beyond AZA dose, depending on pattern of thiopurine me-
tabolites (eg, adding allopurinol in shunters,86,87 switching
out of treatment class if active symptoms occur despite
Table 9. In Patients With Inflammatory Bowel Disease Treated With Thiopurines, Is Routine Therapeutic Drug Monitoring (Thiopurine Metabolite Monitoring) to Guide
Thiopurine Dosing Superior to Empiric Weight-Based Dosing?83,84
No. of
participants
(studies),
follow-up
Quality assessment Summary of findings
Risk of
bias Inconsistency Indirectness Imprecision
Publication
bias
Overall
quality of
evidence
Study event rates,
n (%)
Relative effect,
RR (95% CI)
Anticipated absolute
effects
With
weight-
based
dosing
With thiopurine
metabolite-
guided
dosing
Risk with
weight-
based
dosing
Risk difference
with thiopurine
metabolite-
guided
dosing
Clinical remission
(critical outcome)
107 (2 RCTs) Not serious Seriousa Not serious Very seriousb None 44
LOW
18/57
(31.6%)
21/50
(42.0)
1.44
(0.593.52)
316 per
1000
139 more per
1000 (129
fewer to
796 more)
Discontinuation of
therapy (due to
drug-related
adverse events)
(critical outcome)
107 (2 RCTs) Not serious Seriousa Not serious Very seriousb None 44
LOW
15/57
(26.3)
16/50
(32.0)
1.20
(0.502.91)
263 per
1000
53 more per
1000 (132
fewer to
503 more)
RR, risk ratio.
aI2 > 50%.
bWide CIs crossing 1, and low event rate.
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SECTIONtherapeutic 6-TGN), these clinical trials did not allow for
these potential therapeutic interventions and did not study
the entire scope of possible interventions with routine
knowledge of thiopurine metabolites. Additionally, included
clinical trials were unable to address the potential benefit of
routine 6-TGN monitoring in identifying and appropriately
treating noncompliant patients, given low observed rates of
noncompliance in clinical trials (Hawthorne effect). Finally,
both of these trials were conducted almost a decade ago,
and since the conduct of these trials, treatment paradigms
have evolved, including consideration for early introduction
of biologic therapies in the management of IBD patients,
considering a “top-down” strategy over a “step-up”
approach, which limits the applicability of these trials in the
current scenario. Current evidence is very limited in terms
of understanding the potential benefit of routine thiopurine
metabolite testing over standard weight-based dosing in
thiopurine-treated patients. There are very limited data on
the cost-effectiveness of a strategy of routine thiopurine
metabolite monitoring.Knowledge Gaps and Future Directions
We have identified the following key knowledge gaps in
the role of TDM in IBD, particularly with biologic agents
(anti-TNF and non-anti-TNF), which should be addressed in
properly designed studies. Observational and comparative
evidence is needed to define minimal effective exposure
thresholds that are associated with clinically meaningful
outcomes after induction and maintenance therapy; simi-
larly, the maximum threshold concentration beyond which a
ceiling effect is observed (ie, above which further attempts
at increased trough concentrations is highly unlikely to be
effective) needs to be identified, acknowledging that such
thresholds may be different for different outcomes of in-
terest (eg, clinical remission, endoscopic remission, fistula
healing, management of CD after surgically induced remis-
sion, and left-sided UC vs pan-UC). Once thresholds are
identified, randomized trials comparing the efficacy and
safety of early optimized therapy based on TDM to target
trough concentration(s) vs standard induction dosing
should be evaluated. For patients on maintenance therapy,
adequately powered and well-designed randomized studies
(with appropriate trough concentration and ADAb threshold
defined algorithms) are needed to compare reactive TDM vs
routine proactive TDM vs empiric treatment changes, eval-
uating long-term patient-important outcomes. To ascertain
the frequency of performing measurements in the setting of
proactive TDM, adequately powered randomized studies
comparing, for example, one-time proactive TDM vs annual
proactive TDM vs more frequent TDM, are warranted. These
trials may need to be performed in different disease phe-
notypes, as differences in exposureresponse relationships
(eg, CD vs UC) became apparent for infliximab. With the
availability of different drug assays, inter-assay reliability
assessments for both trough concentrations and ADAbs are
urgently warranted to guarantee reproducible clinical de-
cision making across the different diagnostic platforms.
Besides trough concentrations, comprehensive analyses ofpersistent vs transient ADAbs and low- and high-titer
ADAbs need to be performed to optimally inform TDM al-
gorithms. Once these thresholds are well-defined, then
clinical trials comparing exposure-based dosing vs fixed
dosing are required to facilitate optimization of biologic
agents. There is a lack of data on the exposureresponse
relationship of biologics with a mechanism of action other
than blockage of TNF, which commands in-depth studies
linking exposure to target engagement and patient-
important outcomes, instead of direct extrapolation from
anti-TNF agents. Current therapeutic approaches favor a
combination therapy of a thiopurine with a biologic rather
than monotherapy. Prospective evaluations regarding target
6-TGN concentrations to prevent antibody formation or to
optimize clinical efficacy in patients on a concomitant bio-
logic and a thiopurine are warranted.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
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Supplementary Methods
Search Strategy
To inform evidence pertaining to these focused questions, a
systematic literature search of multiple electronic databases on
TDM in IBDs was conducted by an experienced medical
librarian using a combination of controlled vocabulary sup-
plemented with keywords, with input from the technical review
authors. The search was conducted from inception to March 6,
2016, and the databases included: Ovid Medline In-Process &
Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE and
Ovid Cochrane Database of Systematic Reviews (detailed search
strategy listed below). Technical review context experts and
methodologist (SS) independently reviewed the title and ab-
stract of studies identified in the search to exclude studies that
did not address the focused question based on prespecified
inclusion and exclusion criteria. The full text of the remaining
articles was examined to determine whether it contained
relevant information, and relevant articles at end of this pro-
cess were selected for each question. Conflicts in study selec-
tion at this stage were resolved by consensus, referring back to
the original article in consultation with clinical content experts.
This search was supplemented with a recursive search of the
bibliographies of recently published systematic reviews on this
topic, to identify any additional studies. We also reviewed
conference proceedings from major gastroenterology confer-
ences from 2011 through 2016, and contacted experts in the
field for any potential unpublished studies. We restricted our
search to English language and human studies. Filters were
applied to exclude editorials, letters to the editor and case
reports.
Electronic Search Strategy
Search date: March 6, 2016
Databases searched: Ovid MEDLINE 1946 to February Week
4 2016, Ovid MEDLINE In-Process & Other Non-Indexed Cita-
tions March 04, 2016, Embase 1980 to 2016 Week 10, Wiley
Cochrane.
No. Searches Results
1 exp Inflammatory Bowel Diseases/ use mesz 64,883
2 exp inflammatory bowel disease/ use emez 100,911
3 (ibd or inflammatory bowel disease* or colitis or
crohn*).ti,ab.
216,329
4 (((enteritis or leitis or ileitides) adj2 (terminal or regional
or granulomatous)) or ileocolitis).ti,ab.
2753
5 or/1-4 246,619
6 exp Antibodies, Monoclonal/ use mesz 192,104
7 exp monoclonal antibody/ use emez 396,863
8 (Infliximab or remicade or adalimumab or humira or
certolizumab pegol or Cimzia or golimumab or
Simponi or vedolizumab or Entyvio).ti,ab.
33,037
9 or/6-8 592,430
10 exp Azathioprine/ 89,349
11 exp 6-Mercaptopurine/ use mesz 18,207
12 exp mercaptopurine/ use emez 21,019
Continued
No. Searches Results
13 (6-Mercaptopurine or 6-MP or Purinethol or Purixan
or azothioprine or Azathioprine or Azasan or
Imuran).ti,ab.
38,217
14 (thiopurine adj2 (therap* or treatment*)).ti,ab. 919
15 or/10-14 117,795
16 5 and (9 or 15) 34,290
17 exp Drug Monitoring/ 59,744
18 exp Guanine Nucleotides/ use mesz 50,692
19 exp guanine nucleotide/ use emez 4993
20 exp Thioguanine/ use mesz 2449
21 exp tioguanine/ use emez 7780
22 exp Methyltransferases/ use mesz 35,464
23 exp thiopurine methyltransferase/ use emez 2023
24 exp Thionucleotides/ use mesz 10,136
25 exp nucleotide/ use emez 486,603
26 ((anti?drug* or anti?infliximab or anti?adalimumab or
anti?Certolizumab pegol or anti?vedolizumab or
anti?golimumab or Human Anti?chimeric or HACA
or anti?remicade or anti?humira or anti?cimzia or
anti?simponi
or anti?entyvio) adj2 anti?bod*).ti,ab.
657
27 (therapeutic adj2 monitor*).ti,ab. 19,666
28 (thiopurine methyltransferase or tpmt or thiopurine S?
methyltransferase or 6?thioguanine* or 6?tgn or
6?methylmercaptopurine ribonucleotide* or 6?
MMP or 6?MMPR).ti,ab.
2539
29 ((drug* or medication* or biologic* or infliximab or
adalimumab or Certolizumab pegol or
vedolizumab or golimumab or thiopurine* or 6?
Mercaptopurine or Azathioprine or anti?bod* or
metabolite* or metabolism or anti?bod*)
adj2 (concentration* or measure* or level* or
monitor* or test*)).ti,ab.
325,351
30 (trough or assay* or immuno?assay* or radioimmuno?
assay* or elisa or phenotype or gentotype).ti,ab.
2,696,842
31 or/17-30 3,504,924
32 16 and 31 5282
33 Case Reports/ or Comment.pt. or Editorial.pt. or
Letter.pt.
4,456,599
34 Case Report/ or Comment/ or Editorial/ or Letter/ 6,290,700
35 animals/ not (humans/ and animals/) 5,310,359
36 32 not (33 or 34 or 35) 4795
37 limit 36 to english language 4605
38 limit 37 to yr ¼ “2000 -Current” 4412
39 remove duplicates from 38 3659
Wiley Cochrane
ID Search Hits
#1 MeSH descriptor: [Inflammatory Bowel Diseases] explode
all trees
2246
#2 (ibd or inflammatory bowel disease* or colitis or
crohn*):ti,ab
4129
#3 (((enteritis or leitis or ileitides) near/2 (terminal or regional
or granulomatous)) or ileocolitis):ti,ab
25
#4 #1 or #2 or #3 4261
#5 MeSH descriptor: [Antibodies, Monoclonal] explode all
trees
6272
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Continued
#6 (Infliximab or remicade or adalimumab or humira or
certolizumab pegol or Cimzia or golimumab or
Simponi or vedolizumab or Entyvio):ti,ab
2020
#7 #5 or #6 7369
#8 MeSH descriptor: [Azathioprine] explode all trees 1099
#9 MeSH descriptor: [6-Mercaptopurine] explode all trees 1310
#10 (6-Mercaptopurine or 6-MP or Purinethol or Purixan or
azothioprine or Azathioprine or Azasan or Imuran):ti,ab
1730
#11 (thiopurine near/2 (therap* or treatment*)):ti,ab 22
#12 #8 or #9 or #10 or #11 2238
#13 #4 and (#7 or #12) 805
#14 MeSH descriptor: [Drug Monitoring] explode all trees 1319
#15 MeSH descriptor: [Guanine Nucleotides] explode all trees 272
#16 MeSH descriptor: [Thioguanine] explode all trees 175
#17 MeSH descriptor: [Methyltransferases] explode all trees 284
#18 MeSH descriptor: [Thionucleotides] explode all trees 59
#19 ((anti*drug* or anti*infliximab or anti*adalimumab or
anti*Certolizumab pegol or anti*vedolizumab or
anti*golimumab or Human Anti*chimeric or HACA or
anti*remicade or anti*humira or anti*cimzia or
anti*simponi or anti*entyvio) near/2 anti*bod*):ti,ab
30
#20 (therapeutic near/2 monitor*):ti,ab 371
#21 (thiopurine methyltransferase or tpmt or thiopurine
S-methyltransferase or 6*thioguanine* or 6*tgn or
6*methylmercaptopurine ribonucleotide* or 6*MMP or
6*MMPR):ti,ab
58
#22 ((drug* or medication* or biologic* or infliximab or
adalimumab or Certolizumab pegol or vedolizumab or
golimumab or thiopurine* or 6*Mercaptopurine or
Azathioprine or anti*bod* or metabolite* or metabolism
or anti*bod*) near/2 (concentration* or measure* or
level* or monitor* or test*)):ti,ab
13205
#23 (trough or assay* or immuno*assay* or
radioimmuno*assay* or elisa or phenotype or
gentotype).ti,ab.
293
#24 #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or
#22 or #23
15351
#25 #13 and #24 Publication Year from 2000 to 2016 91
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Supplementary Table 1.Main Characteristics of Assays Currently Available in the United States
Assay Target Phase LLOQ Drug tolerant Provider
ELISA Adalimumab Solid 0.1 mg/mL / Miraca
Anti-adalimumab Abs Solid 10 ng/mL No Miraca
Infliximab Solid 0.1 mg/mL / Miraca
Anti-infliximab Abs Solid 10 ng/mL No Miraca
Certolizumab pegol Solid 0.4 mg/mL / Miraca
Anti-certolizumab pegol Abs Solid 10 ng/mL No Miraca
Vedolizumab Solid 2 mg/mL / Miraca
Anti-vedolizumab Abs Solid 35 ng/mL No Miraca
Ustekinumab Solid 0.2 mg/mL / Miraca
Anti-ustekinumab Abs Solid 5 ng/mL No Miraca
Anti-infliximab Abs Solid 50 U/mL No Mayo
HMSA Adalimumab Fluid 1.6 mg/mL / Prometheus
Anti-adalimumab Abs Fluid 1.7 U/mL Yes Prometheus
Infliximab Fluid 0.98 mg/mL / Prometheus
Anti-infliximab Abs Fluid 3.13 U/mL Yes Prometheus
Vedolizumab Fluid 1.6 mg/mL / Prometheus
Anti-vedolizumab Abs Fluid 1.6 U/mL Yes Prometheus
LC-MS/MS Infliximab Fluid 1.0 mg/mL / Mayo
ECLIA Adalimumab Fluid 0.6 mg/mL / Esoterix
Anti-adalimumab Abs Fluid 25 ng/mL Yes Esoterix
Infliximab Fluid 0.4 mg/mL / Esoterix
Anti-infliximab Abs Fluid 22 ng/mL Yes Esoterix
ADAb, anti-drug antibody; LC-MS/MS, liquid chromatography tandem mass spectrometry; LLOQ, lower limit of quantification.
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Supplementary Table 2.Characteristics of Cohort Studies Evaluating the Impact of Reactive Therapeutic Drug Monitoring for Tumor Necrosis Factor Antagonists
First author, year Patients, n Drug Inclusion Intervention
Therapeutic
trough
Low
ADAbs High ADAbs
Paul, 201323
(prospective)
52 (34 CD and 18 UC) Infliximab
5 mg/kg q8 wk
CD: CDAI 220 AND CRP >10 mg/L OR
FC >450 mg/g
UC/IC: SCCAI 3 AND endoscopic Mayo score >1
10 mg/kg q8 wk 2 mg/mL >10 ng/mL and
<200 ng/mL
>200 ng/mL
Roblin, 201425
(prospective)
82 (46 CD and 36 UC) Adalimumab
40 mg EOW
CD: CDAI 220 AND FC >450 mg/gUC: Mayo clinic
score >5 AND endoscopic Mayo score >1
40 mg EW 4.9 mg/mL >10 ng/mL
Yanai, 201524
(retrospective)
247 patients (199 CD,
48 UC or IBD-
unclassified)
Maintenance
infliximab
Clinical worsening by the treating physician, or definite
inflammatory loss of response if clinical worsening
was associated with either increased CRP or FC,
active endoscopic inflammation, fistula discharge,
or compatible imaging studies
Dose intensification/
switch anti-TNF
agent/expectant
management
3.8 mg/mL >4 mg/mL
equivalents
Maintenance
adalimumab
4.5 mg/mL >9 mg/mL
equivalents
CDAI, Crohn’s disease activity index; EOW, every other week; EW, every week; FC, fecal calprotectin; IC, indeterminate colitis; SCCAI, Simple Clinical Colitis Activity Index.
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Supplementary Table 3.Proportion of Patients With Ulcerative Colitis or Crohn’s Disease, Not in Remission, at Different
Infliximab Cutoffs in Cross-Sectional or Cohort Studies Which Reported Outcomes at Several
Predefined Cutoffs
Infliximab trough concentration
threshold, mg/mL
Patients not in clinical remission
UC CD
% (95% CI) No. of studies % (95% CI) No. of studies
1 32.7 (16.854.0) 3 19.7 (13.927.1) 3
3 16.6 (7.134.4) 3 11.8 (7.717.7) 3
5 10.1 (4.321.9) 3 6.7 (3.711.7) 3
7 3.6 (0.619.2) 3 4.5 (1.116.0) 2
10 2.8 (0.235.3) 2 3.5 (1.96.4) 2
Supplementary Table 4.Metabolite-Directed Algorithm for Clinical Strategies in Patients With Inflammatory Bowel Disease
and an Inadequate Response to Thiopurine Therapy (as Proposed in Haines et al76)
6-TGN level 6-MMP level Interpretation Proposed management strategy
Therapeutic
(230450 pmol/8  108 RBCs)
Normal or high Thiopurine-refractory, appropriately
dosed
Change therapy; if thiopurine
continued, no change in dose
Low (<230 pmol/8  108 RBCs) Low or normal Underdosed, or
noncompliant (if both 6-TGN and
6-MMP low, and questioning
patient)
Increase dose; if noncompliant,
then education about compliance
High (>450 pmol/8  108 RBCs) High or normal Thiopurine-refractory, overdosed Change therapy
Low (<230 pmol/8  108 RBCs) High (>5700), with
6-MMP/6TGN ratio >11
6-MMP shunter Change therapy or add allopurinol and
reduce thiopurine dose to 25%
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Supplementary Table 5. Impact of Thiopurine Metabolite Testing on Effectiveness and Safety in Observational Studies
First author,
year
Patients in
study, n
Reason for TDM
Outcomes based on TDM results
Inadequate
response AEs
Mardini, 200381 44 31 13 (7 abnormal LFTs, 2
leukopenia, 4 anemia)
Treatment change reported only for subtherapeutic:
11 of 19 (58%) remission after dose increase
Resolution of AE: overall, 6 of 13 (46%); LFTs: 5 of
7 (71%); leukopenia: 1 of 2 (50%)
Kennedy, 201380 98 80 18 (6 abnormal LFTs, 5
leukopenia, 7 other AEs)
Improved clinical outcome (which includes increasing
thiopurines, adding allopurinol, switch of therapy
including surgery): 44 of 80 (55%)
Resolution AE after TDM: overall, 5 of 18 (28%); LFTs: 1 of
6 (17%); leukopenia: 2 of 5 (40%); other AEs: 2 of 7
(29%).
Smith, 201382 189 53 NR Improvement of 18 of 20 (90%) with treatment change
based on 6-TGN vs 7 of 21 (33%) in treatment changes
not based on 6-TGN levels
Goldberg, 201679 151 116 30a Change of therapy in 78 of 116 (67%) and 18 of 30 (60%)a
Total 545 343 61
AE, adverse event; LFT, liver function test; NR, not reported.
aIncludes patients with side effects and other indications for drug monitoring.
September 2017 AGA Review of Therapeutic Drug Monitoring in IBD 857.e6
